We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+28.76%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$361M
AUM Growth
+$55.4M
Cap. Flow
+$39.7M
Cap. Flow %
10.98%
Top 10 Hldgs %
40.07%
Holding
85
New
33
Increased
24
Reduced
13
Closed
13

Top Buys

1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$11.9M
2
TGTX icon
TG Therapeutics
TGTX
+$9.16M
3
APLS
Apellis Pharmaceuticals
APLS
+$8.29M
4
ROIV icon
Roivant Sciences
ROIV
+$7.55M
5
VRDN icon
Viridian Therapeutics
VRDN
+$6.3M

Top Sells

1
AMAM
Ambrx Biopharma Inc
AMAM
+$6.76M
2
ARGX icon
argenx
ARGX
+$5.71M
3
KRYS icon
Krystal Biotech
KRYS
+$5M
4
GPCR icon
Structure Therapeutics
GPCR
+$3.16M
5
ATXS
Astria Therapeutics
ATXS
+$2.74M

Sector Composition

1 Healthcare 85.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
76
Ascendis Pharma A/S
ASND
$17.1B
– –
-20,000
Closed -$2.52M
BLUE
77
DELISTED
bluebird bio
BLUE
– –
-23,250
Closed -$642K
IWM icon
78
CALL
iShares Russell 2000 ETF
IWM
$82.2B
– –
-250,000
Closed -$50.2M
MLTX icon
79
CALL
MoonLake Immunotherapeutics
MLTX
$1.64B
– –
-250,000
Closed -$15.1M
RVMD icon
80
PUT
Revolution Medicines
RVMD
$39.6B
– –
-75,000
Closed -$2.15M
VRNA
81
DELISTED
Verona Pharma
VRNA
– –
-30,000
Closed -$596K
XBI icon
82
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-250,000
Closed -$22.3M
CBAY
83
DELISTED
Cymabay Therapeutics
CBAY
– –
-90,000
Closed -$2.13M
AMAM
84
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-475,000
Closed -$6.76M
INBX
85
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-35,000
Closed -$1.33M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ghost Tree Capital held 85 positions worth $361M, up 18% from $306M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital deployed $39.7M of net new capital in Q1 2024, opening 33 new positions and adding to 24 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 56% a quarter earlier.

On the sell side, the largest reduction was Krystal Biotech, an estimated $5M trimmed.

  • Ghost Tree Capital's largest Q1 2024 buy was Apellis Pharmaceuticals: 130,000 shares worth $7.64M.
  • Ghost Tree Capital added most to MoonLake Immunotherapeutics in Q1 2024, an estimated $11.9M increase.
  • Ghost Tree Capital's biggest Q1 2024 reduction was Krystal Biotech, cutting an estimated $5M.
  • Ghost Tree Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $6.76M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $361M portfolio in Q1 2024.
  • Ghost Tree Capital opened 33 new positions and closed 13 in Q1 2024.
  • Ghost Tree Capital's portfolio value rose 18% quarter-over-quarter to $361M.

Based on Ghost Tree Capital's 13F filing for Q1 2024, filed 15 May 2024.